Loading...

Pfenex

DB:26P
Snowflake Description

Flawless balance sheet with high growth potential.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
26P
DB
$185M
Market Cap
  1. Home
  2. DE
  3. Pharmaceuticals & Biotech
Company description

Pfenex Inc., a clinical-stage development and licensing biotechnology company, focuses on developing protein therapies for unmet patient needs. The last earnings update was 37 days ago. More info.


Add to Portfolio Compare Print
  • Pfenex has significant price volatility in the past 3 months.
26P Share Price and Events
7 Day Returns
-8.9%
DB:26P
0.3%
DE Biotechs
2.3%
DE Market
1 Year Returns
12.6%
DB:26P
-7.9%
DE Biotechs
-7.2%
DE Market
26P Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Pfenex (26P) -8.9% 15.2% 45.1% 12.6% -40.7% -
DE Biotechs 0.3% 3.1% -6.5% -7.9% 43.5% 7.6%
DE Market 2.3% 3.1% 8.8% -7.2% 9.3% 12.3%
1 Year Return vs Industry and Market
  • 26P outperformed the Biotechs industry which returned -7.9% over the past year.
  • 26P outperformed the Market in Germany which returned -7.2% over the past year.
Price Volatility
26P
Industry
5yr Volatility vs Market

Value

 Is Pfenex undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for Pfenex. This is due to cash flow or dividend data being unavailable. The share price is €4.92.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Pfenex's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Pfenex's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:26P PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-12-31) in USD $-1.40
AMEX:PFNX Share Price ** AMEX (2019-04-17) in USD $5.88
Europe Biotechs Industry PE Ratio Median Figure of 30 Publicly-Listed Biotechs Companies 23.37x
Germany Market PE Ratio Median Figure of 422 Publicly-Listed Companies 19.43x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Pfenex.

DB:26P PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= AMEX:PFNX Share Price ÷ EPS (both in USD)

= 5.88 ÷ -1.40

-4.21x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Pfenex is loss making, we can't compare its value to the Europe Biotechs industry average.
  • Pfenex is loss making, we can't compare the value of its earnings to the Germany market.
Price based on expected Growth
Does Pfenex's expected growth come at a high price?
Raw Data
DB:26P PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -4.21x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 2 Analysts
49.9%per year
Europe Biotechs Industry PEG Ratio Median Figure of 22 Publicly-Listed Biotechs Companies 1.31x
Germany Market PEG Ratio Median Figure of 272 Publicly-Listed Companies 1.56x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Pfenex, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Pfenex's assets?
Raw Data
DB:26P PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-12-31) in USD $1.94
AMEX:PFNX Share Price * AMEX (2019-04-17) in USD $5.88
Germany Biotechs Industry PB Ratio Median Figure of 15 Publicly-Listed Biotechs Companies 3.89x
Germany Market PB Ratio Median Figure of 570 Publicly-Listed Companies 1.87x
DB:26P PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= AMEX:PFNX Share Price ÷ Book Value per Share (both in USD)

= 5.88 ÷ 1.94

3.03x

* Primary Listing of Pfenex.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Pfenex is good value based on assets compared to the DE Biotechs industry average.
X
Value checks
We assess Pfenex's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. Pfenex has a total score of 1/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is Pfenex expected to perform in the next 1 to 3 years based on estimates from 2 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
49.9%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Pfenex expected to grow at an attractive rate?
  • Pfenex's earnings growth is expected to exceed the low risk savings rate of 0.2%.
Growth vs Market Checks
  • Pfenex's earnings growth is expected to exceed the Germany market average.
  • Pfenex's revenue growth is expected to exceed the Germany market average.
Annual Growth Rates Comparison
Raw Data
DB:26P Future Growth Rates Data Sources
Data Point Source Value (per year)
DB:26P Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 2 Analysts 49.9%
DB:26P Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 2 Analysts 37.2%
Germany Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 47.6%
Germany Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 26.1%
Germany Market Earnings Growth Rate Market Cap Weighted Average 11.7%
Germany Market Revenue Growth Rate Market Cap Weighted Average 4.8%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:26P Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 2 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:26P Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2023-12-31 210 120 1
2022-12-31 192 107 1
2021-12-31 159 97 1
2020-12-31 92 36 1
2019-12-31 35 -41 2
DB:26P Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2018-12-31 15 -39 -40
2018-09-30 29 -19 -27
2018-06-30 31 -17 -25
2018-03-31 30 -21 -27
2017-12-31 29 -22 -26
2017-09-30 16 -43 -42
2017-06-30 60 -27 2
2017-03-31 60 -24 4
2016-12-31 60 -22 5
2016-09-30 58 -20 7
2016-06-30 11 -32 -35
2016-03-31 10 -31 -30

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Pfenex's earnings are expected to grow significantly at over 20% yearly.
  • Pfenex's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:26P Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 2 Analyst Estimates (S&P Global) See Below

All data from Pfenex Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:26P Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2023-12-31 3.18 3.18 3.18 1.00
2022-12-31 2.94 2.94 2.94 1.00
2021-12-31 2.78 2.78 2.78 1.00
2020-12-31 1.06 1.06 1.06 1.00
2019-12-31 -0.57 0.17 -1.30 2.00
DB:26P Past Financials Data
Date (Data in USD Millions) EPS *
2018-12-31 -1.40
2018-09-30 -1.04
2018-06-30 -1.04
2018-03-31 -1.13
2017-12-31 -1.09
2017-09-30 -1.78
2017-06-30 0.06
2017-03-31 0.16
2016-12-31 0.23
2016-09-30 0.32
2016-06-30 -1.48
2016-03-31 -1.32

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Pfenex will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess Pfenex's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Pfenex has a total score of 5/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has Pfenex performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Pfenex's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Pfenex does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare Pfenex's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Pfenex's 1-year growth to the Europe Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
Pfenex's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Pfenex Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:26P Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-12-31 14.86 -39.59 16.25 33.44
2018-09-30 29.42 -27.28 15.95 35.48
2018-06-30 30.87 -25.44 16.12 34.55
2018-03-31 29.71 -26.68 16.76 34.01
2017-12-31 28.78 -25.68 18.00 31.60
2017-09-30 16.34 -41.81 18.74 35.00
2017-06-30 60.14 1.50 19.15 35.58
2017-03-31 60.25 3.66 19.18 32.97
2016-12-31 60.19 5.48 17.70 32.05
2016-09-30 57.98 7.45 16.93 27.60
2016-06-30 11.22 -34.64 15.80 24.59
2016-03-31 10.37 -30.45 15.16 20.61
2015-12-31 9.58 -28.22 14.85 17.94
2015-09-30 8.34 -23.12 13.99 13.34
2015-06-30 9.09 -17.14 13.16 8.91
2015-03-31 10.06 -13.79 11.50 6.16
2014-12-31 10.64 -9.79 9.10 4.03
2014-09-30 12.86 -7.13 7.78 4.02
2014-06-30 12.04 -7.63 6.93 4.80
2014-03-31 11.09 -6.60 6.54 5.26
2013-12-31 11.91 -5.76 6.87 5.32
2012-12-31 11.29 -4.18 6.96 1.71

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Pfenex has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Pfenex has efficiently used its assets last year compared to the Europe Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Pfenex improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Pfenex's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Pfenex has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is Pfenex's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Pfenex's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Pfenex is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Pfenex's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Pfenex's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Debt is covered by short term assets, assets are 125.5x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Pfenex Company Filings, last reported 3 months ago.

DB:26P Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2018-12-31 61.14 0.51 56.22
2018-09-30 67.32 0.59 67.83
2018-06-30 77.06 0.67 80.19
2018-03-31 47.76 0.75 47.06
2017-12-31 57.76 0.65 57.66
2017-09-30 51.65 0.71 48.37
2017-06-30 59.64 0.00 59.88
2017-03-31 71.12 0.00 70.20
2016-12-31 80.15 0.08 81.50
2016-09-30 89.93 0.00 93.64
2016-06-30 54.56 0.00 89.60
2016-03-31 63.94 0.00 96.53
2015-12-31 71.18 3.81 106.16
2015-09-30 79.19 3.81 115.92
2015-06-30 86.19 3.81 123.00
2015-03-31 54.33 3.81 92.00
2014-12-31 59.87 3.81 45.72
2014-09-30 63.24 3.81 51.50
2014-06-30 15.10 3.81 3.94
2014-03-31 16.98 3.59 5.00
2013-12-31 18.73 3.59 5.20
2012-12-31 22.64 1.14 9.97
  • Pfenex's level of debt (0.8%) compared to net worth is satisfactory (less than 40%).
  • The level of debt compared to net worth has been reduced over the past 5 years (19.2% vs 0.8% today).
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Pfenex has sufficient cash runway for 1.4 years based on current free cash flow.
  • Pfenex has sufficient cash runway for 1.3 years if free cash flow continues to grow at historical rates of 21.3% each year.
X
Financial health checks
We assess Pfenex's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Pfenex has a total score of 6/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is Pfenex's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Pfenex dividends.
If you bought €2,000 of Pfenex shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Pfenex's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Pfenex's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:26P Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 2 Analyst Estimates (S&P Global) See Below
Europe Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 9 Stocks 0.9%
Germany Market Average Dividend Yield Market Cap Weighted Average of 325 Stocks 3.1%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.8%
Germany Bottom 25% Dividend Yield 25th Percentile 1.4%
Germany Top 25% Dividend Yield 75th Percentile 3.7%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

DB:26P Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2023-12-31
2022-12-31
2021-12-31
2020-12-31
2019-12-31

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Pfenex has not reported any payouts.
  • Unable to verify if Pfenex's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Pfenex's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Pfenex has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Pfenex's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Pfenex afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Pfenex has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of Pfenex's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Eef Schimmelpennink
COMPENSATION $1,408,428
AGE 46
TENURE AS CEO 1.7 years
CEO Bio

Mr. Evert Schimmelpennink, also known as Eef, has been Chief Executive Officer, President and Secretary of Pfenex Inc. since August 3, 2017. Mr. Schimmelpennink served as Chief Executive Officer at ALVOTECH ehf from 2015 to July 3, 2017. He has over 18 years of global generic pharmaceutical experience and has a strong record of accomplishment of delivering profitable growth. Prior to joining Alvotech, he served as Vice President of Global at Sterile Injectibles Pfizer from September 2015 to November 2015. He served as Vice President of Global Generics at Hospira from 2012 to 2015 and Director of Specialty Injectable Pharma Marketing EMEA & Director of Distributor Operations EMEA from 2011 to 2012 of Hospira, Inc. From 2002 to 2011, he has also held various senior commercial leadership positions at Synthon BV, including Vice President Marketing and Sales from 2008 to 2011. From 1997 to 2002, he held various roles with Numico NV, including International Product Manager from 2000 to 2002 and Researcher Product Development from 1999 to 2000. Prior to Numico, Mr. Schimmelpennink served as a vaccine technologist at the Dutch National Institute for Public Health and the Environment from 1998 to 1999. He has been a Director of Pfenex Inc. since August 3, 2017. Mr. Schimmelpennink received a Master’s in bioprocess engineering from the Wageningen University in the Netherlands.

CEO Compensation
  • Insufficient data for Eef to compare compensation growth.
  • Eef's remuneration is higher than average for companies of similar size in Germany.
Management Team Tenure

Average tenure and age of the Pfenex management team in years:

1.2
Average Tenure
50
Average Age
  • The average tenure for the Pfenex management team is less than 2 years, this suggests a new team.
Management Team

Eef Schimmelpennink

TITLE
CEO, President
COMPENSATION
$1M
AGE
46
TENURE
1.7 yrs

Patricia Lady

TITLE
Chief Accounting Officer
COMPENSATION
$398K
AGE
60
TENURE
8.3 yrs

Patrick Lucy

TITLE
Senior VP & Chief Business Officer
COMPENSATION
$1M
AGE
50
TENURE
10.3 yrs

Hubert Chen

TITLE
COMPENSATION
$904K
AGE
49
TENURE
0.6 yrs

Susan Knudson

TITLE
Senior VP & CFO
AGE
54
TENURE
1.2 yrs

Shawn Scranton

TITLE
Senior VP & COO
AGE
54
TENURE
0.5 yrs

Martin Brenner

TITLE
Senior VP & Chief Scientific Officer
AGE
47
TENURE
0.1 yrs
Board of Directors Tenure

Average tenure and age of the Pfenex board of directors in years:

2.4
Average Tenure
56
Average Age
  • The average tenure for the Pfenex board of directors is less than 3 years, this suggests a new board.
Board of Directors

Jason Grenfell-Gardner

TITLE
Chairman of the Board
COMPENSATION
$114K
AGE
43
TENURE
1.9 yrs

Eef Schimmelpennink

TITLE
CEO, President
COMPENSATION
$1M
AGE
46
TENURE
1.7 yrs

Robin Campbell

TITLE
Independent Director
COMPENSATION
$108K
AGE
63
TENURE
4.6 yrs

Phil Schneider

TITLE
Independent Director
COMPENSATION
$112K
AGE
62
TENURE
4.8 yrs

John Taylor

TITLE
Independent Director
COMPENSATION
$98K
AGE
53
TENURE
4 yrs

Dennis Fenton

TITLE
Member of Scientific Advisory Board
COMPENSATION
$105K
AGE
66
TENURE
0.2 yrs

Matt Croughan

TITLE
Member of Scientific Advisory Board
TENURE
2.5 yrs

Greg Blank

TITLE
Member of Scientific Advisory Board
TENURE
2.5 yrs

Siggi Olafsson

TITLE
Director
COMPENSATION
$99K
AGE
49
TENURE
2.3 yrs

Magda Marquet

TITLE
Director
AGE
59
TENURE
0.2 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
13. Sep 18 Buy Evert Schimmelpennink Individual 11. Sep 18 11. Sep 18 10,000 €4.35 €43,477
13. Sep 18 Buy Phillip Schneider Individual 11. Sep 18 11. Sep 18 11,000 €4.31 €47,365
24. Aug 18 Buy Robin Campbell Individual 22. Aug 18 22. Aug 18 5,000 €4.19 €20,935
X
Management checks
We assess Pfenex's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Pfenex has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Company Info

Description

Pfenex Inc., a clinical-stage development and licensing biotechnology company, focuses on developing protein therapies for unmet patient needs. Its lead product candidates include PF708, a therapeutic equivalent drug candidate to Forteo (teriparatide) for the treatment of osteoporosis; and novel anthrax vaccine candidates, such as Px563L and RPA563 that have completed Phase Ia clinical study. The company also develops PF582, a biosimilar candidate to Lucentis; PF529, a biosimilar to Neulasta; and hematology/oncology products, including PF743, a recombinant crisantaspase, as well as PF745, a recombinant crisantaspase with half-life extension technology. In addition, it has license and supply agreements for CRM197, a non-toxic mutant of diphtheria toxin. Pfenex Inc. is headquartered in San Diego, California.

Details
Name: Pfenex Inc.
26P
Exchange: DB
Founded:
$163,824,165
31,485,199
Website: http://www.pfenex.com
Address: Pfenex Inc.
10790 Roselle Street,
San Diego,
California, 92121,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
AMEX PFNX Common Stock NYSE MKT LLC US USD 19. Jul 2014
DB 26P Common Stock Deutsche Boerse AG DE EUR 19. Jul 2014
Number of employees
Current staff
Staff numbers
71
Pfenex employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/04/17 23:19
End of day share price update: 2019/04/17 00:00
Last estimates confirmation: 2019/04/11
Last earnings filing: 2019/03/11
Last earnings reported: 2018/12/31
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.